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Highlights 
• A review of concurrent chemoradiotherapy in stage 3 non-small cell lung cancer 
• Recent trial data suggests a detriment to dose-escalated radiotherapy in this setting 
• Large degree of heterogeneity in patient, tumour and clinical factors between cases 
• Heterogeneity may be limiting the ability to detect benefits of doseescalation 
• Technology advances may better stratify cases and allow safer doseescalation 
 
Abstract 
The current standard of care for the management of inoperable stage 3 non-small cell lung 
cancer (NSCLC) is concurrent chemoradiotherapy (cCRT) using radiotherapy dose-
fractionation and chemotherapy regimens that were established 3 decades ago. In an 
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attempt to improve the chances of long-term control from cCRT, dose-escalation of the 
radiotherapy dose was assessed in the RTOG 0617 randomised control study comparing 
the standard 60Gy in 30 fractions with a high-dose arm receiving 74Gy in 37 fractions. 
Following the publication of this trial the thoracic oncology community were surprised to 
learn that there was worse survival in the dose-escalated arm and that for now the standard 
of care must remain with the lower dose. In this article we review the RTOG 0617 paper with 
subsequent analyses and studies to explore why the use of dose-escalated cCRT in stage 3 
NSCLC has not shown the benefits that were expected. The overarching theme of this 
opinion piece is how heterogeneity between stage 3 NSCLC cases in terms of patient, 
tumour, and clinical factors may obscure the potential benefits of dose-escalation by causing 
imbalances in the arms of studies such as RTOG 0617. We also examine recent advances 
in the staging, management, and technological delivery of radiotherapy in NSCLC and how 
these may be employed to optimise cCRT trials in the future and ensure that any potential 
benefits of dose-escalation can be detected.  
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The standard of care in inoperable stage 3 non-small cell lung cancer (NSCLC) is concurrent 
chemo-radiotherapy (cCRT) [1]. Despite recent technological advancements, the currently 
used radiotherapy dose fractionation and chemotherapy were devised over 30 years ago [2].  
The majority of patients with stage 3 disease treated with cCRT will eventually progress, 
translating into survival rates at 5 years of 20-30% at best [1,3]. A strategy to potentially 
improve local control is to escalate the dose of radiation delivered to the tumour. Martel et al 
demonstrated a clear dose response relationship in NSCLC, with 84Gy using conventional 
fractionation being required to get 50% probability of tumour control at 3 years [4]. Following 
this a number of early phase studies have investigated the concept of dose-escalation and 
concluded that radiation doses of 74Gy in 37 fractions can be delivered concurrently with 
chemotherapy using strict dose volume constraints for the organs at risk [5–8]. However the 
concept of dose-escalation as a strategy to improve outcome in stage 3 NSCLC is 
challenged by the surprisingly negative finding of the RTOG 0617 trial in which dose-
escalation with cCRT to 74Gy in 37 fractions led to worse survival compared to standard of 
care (60Gy in 30 fractions) [9].  
 
The following article is not a systematic review. It is intended to stimulate discussion 
regarding the disappointing results of RTOG 0617 and to offer solutions on how to improve 
future radiotherapy trials in locally advanced NSCLC. We aim to appraise the recent 
literature on cCRT since the publication of our previous review on this topic in 2014 and to 
identify research direction to optimise and intensify cCRT [3]. A recurring theme throughout 
this piece is the problem with heterogeneity in stage 3 NSCLC and its consequences for the 
results of randomised controlled trials in this field. Heterogeneity is defined as diversity 
between cases of a certain characteristic and in the case of stage 3 NSCLC may refer to 
patient and tumour related differences in burden of disease, anatomical location, histological 
subtype, and tumour and host genomics. In terms of tumour genomics, heterogeneity exists 
at an inter-patient, intra-patient, or intra-tumoural level, however we shall focus on the 
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former. Additional ‘external’ sources of heterogeneity refer to differences in radiotherapy 
technique, quality assurance (QA), diagnostic radiology, and technology. Table 1 
summarises sources of heterogeneity and how they can impact on trial results. We propose 
that in recent trials heterogeneity of stage 3 NSCLC has been a major and overlooked 
confounder in the analysis and clinical interpretation of the findings. We highlight solutions 
that are currently being employed to exploit technological advances in diagnostics, 
radiotherapy planning, and treatment delivery that may enable improved outcomes through 
allowing for heterogeneity and individualisation of treatment. 
 
Current standard of care in inoperable stage 3 NSCLC 
Following the failure to demonstrate the superiority of 74Gy in 37 fractions in RTOG 0617, 
the standard of care for inoperable stage 3 NSCLC patients with good performance status 
remains 60Gy in 30 fractions of 2Gy concurrently with chemotherapy.  This dose is based on 
a study from 1980 that found 60Gy (2Gy/fraction) to be more efficacious than lower doses in 
terms of local control and survival [10]. Over the following 3 decades trials have persistently 
demonstrated the additional benefit of chemotherapy both sequentially and ultimately 
concurrently for patients with stage 3 disease [11]. The optimal chemotherapy regimen is 
unknown with a number of different platinum doublets being used based on studies from the 
1990’s [3].  Recent gains in the management of stage 4 NSCLC have not translated to 
benefits in the management of stage 3 disease. For example, despite the superiority of 
pemetrexed with cisplatin in the management of metastatic non-squamous NSCLC [12], a 
study of non-metastatic disease failed to show superiority of the same regimen over 
etopside / cisplatin when given concurrently in stage 3 non-squamous disease [13]. 
Furthermore, tyrosine kinase inhibitors successfully used in stage 4 disease against genetic 
targets, such as epidermal growth factor receptor (EGFR) [14], are not used in the stage 3 
setting regardless of the driver mutation (although work is on-going to detect any potential 
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benefits) [15][16](ClinicalTrials.gov:NCT01822496). Therefore most centres are using 
regimens that have barely changed over the last 30 years. Advances in radiotherapy 
delivery, quality assurance (QA), staging and supportive healthcare have enabled 
improvements in survival for this cohort of patients [17]. However it remains that cCRT for 
stage 3 NSCLC is currently given in a ‘one size fits all’ basis despite great variability in the 
clinical and pathological features of this broad group of patients. 
 
Staging and anatomical heterogeneity 
The American Joint Committee on Cancer (AJCC) staging for stage 3 NSCLC is presented 
in Figure 1A [18]. Stage 3 encompasses a diverse spectrum of clinical presentations. It can 
refer to a small peripheral primary with chest wall involvement and solitary hilar node or a 
large 10cm tumour centrally located invading the mediastinum with diffuse mediastinal and 
supraclavicular lymph node involvement (Figure 1B). Such diverse presentations are 
because the TNM classification was primarily created to stratify the operability of lung 
tumours based on organ involvement and size. Technological advances in non-surgical 
therapies are not adequately accounted for. A number of studies of non-surgical radical 
patients show superior prognostic factors to the TNM system. For example, a single 
institution study of 270 NSCLC patients treated with radical radiotherapy found that overall 
gross tumour volume (GTV) and number of positive lymph nodes on PET was a better 
predictor of prognosis than TNM staging [19]. The importance of GTV as a prognostic factor 
has been demonstrated since [20–22], yet patients in the RTOG 0617 study were not 
stratified for GTV volume. Limitations of TNM staging are demonstrated for surgical patients, 
and most marked for the N-stage [23]. In N2 disease the number of nodal stations involved 
is a poor prognostic factor for survival in a multivariate analysis of patients undergoing 
surgery [23]. In a study of 702 patients the 5-year overall survival (OS) for patients with 
radiologically undetectable nodes subsequently confirmed after surgery, was 35% versus 
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13% for one compared with more than one lymph-node station involved. A further study has 
demonstrated that in N1/2 disease the number of lymph nodes positive at surgery is a better 
predictor for survival than AJCC nodal classification [24]. In non-surgical cases a study of 
148 inoperable IIIA-N2 patients showed that outcome from cCRT correlated better with the 
Japanese Nodal Classification [25] [26]. This classification uses the primary tumour location 
to stratify N2 nodal positivity into limited and extensive groups based on the specific lymph 
node stations involved. In this study both progression free survival (PFS) and OS were 
significantly better in IIIA-N2 patients with limited nodal disease [26]. In RTOG 0617 patients 
were stratified to achieve a similar proportion of IIIA to IIIB in both treatment dose arms but 
the aforementioned data suggests that this is not sufficiently robust to ensure balance for 
prognostic stage and the risk of occult metastatic disease. The rationale for dose-escalation 
studies is that a higher radiotherapy dose will improve local control and thereby improve 
survival. The question then is whether the failure of dose-escalation strategies to date is due 
to a potential imbalance of inclusion of patients that are at high risk for occult metastasis at 
presentation? In both arms of RTOG 0617 one third of patients relapsed with clinically or 
radiologically detectable metastatic disease within 12 months of treatment. Given that local 
relapse is difficult to confirm radiologically (due to post radiotherapy fibrosis) the most 
reliable endpoint to detect treatment failure is OS and an imbalance of risk of metastatic 
disease based on nodal stage could skew results.  
 
The large volume of the lungs within the thorax creates a wide variation in the location of 
tumours with regard to proximity to critical organs such as the heart. In RTOG 0617 the 
heart dose was higher in the high dose arm and a multivariate analysis of the survival data 
for all patients in the study revealed that higher heart V5 and V30 were associated with 
poorer survival [9].  In another study of 333 radical radiotherapy plans the heart was re-
contoured according to RTOG 0617 guidelines and on multivariate analysis heart V50 was 
one of the variables associated with poorer survival [27]. When stratified by V50 heart dose 
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less than 25% versus 25% or greater the 2-year OS rates were 45.9% versus 26.7%. A data 
mining approach at our institute used the collation of approximately 1000 NSCLC radical 
radiotherapy plans to identify irradiated anatomical regions associated with poorer survival 
[28]. The plans were deformed to a reference and dose distributions compared to map dose 
differences between survivors and non-survivors at different time points. This identified a 
dose differential centred over the aorta and the origin of the left coronary artery with a 6Gy 
differential between survivors and non-survivors at 12 months and a 6 month survival 
difference between patients receiving above or below 20.2Gy to this critical region. Most 
recently an analysis was performed on all dose-escalated NSCLC patients (receiving 
between 70 and 90Gy) treated in trials of the Eastern Cooperative Oncology Group between 
1996-2007 [29]. In the 112 patients reviewed, 26 (23%) had one or more cardiac events 
following dose-escalated radiotherapy with a median of 26 months to first event. On 
multivariate analysis, cardiac radiotherapy dose was significantly associated with the 
occurrence of cardiac events with 2-year risk-adjusted event rates of 4%, 7%, and 21% for 
mean heart dose <10Gy, 10 to 20Gy, and >20Gy respectively. Interestingly in this study 
heart doses were not associated with overall survival. RTOG 0617 did not stratify patients 
for tumour location so imbalances in this variable between the two dose arms may have 
contributed to the poorer outcomes seen with dose-escalation. In addition to the heart, 
proximity to other critical structures such as the spinal cord and brachial plexus, as well as 
overall dose to the lungs themselves, may limit the dose deliverable to the tumour and 
prevent dose-escalation. It is also important to consider the degree of respiratory motion 
present as there is variability depending on the location of the tumour in the lung with a 
higher degree of motion affecting lower lobe tumours [30][31]. A higher proportion of lower 
lobe tumours in one arm of a study may increase the incidence of geographic misses to 
worsen the outcome. 
 
Diagnostic heterogeneity  
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Heterogeneity in diagnostic radiology between centres can affect trial outcome interpretation 
in two categories, pre-treatment staging determination and post-treatment recurrence 
detection. The last decade has seen the introduction of FDG PET-CT into routine clinical 
practice for the staging of potentially radically treatable NSCLC. PET-CT increases the 
detection of nodal and metastatic disease to reduce the incidence of occult metastatic 
disease in staging groups [32]. Using PET data in radiotherapy planning improves target 
volume delineation and reduces inter-clinician delineation variability [33]. Pre-treatment PET 
scanning was similar for both groups in RTOG 0617 (89% for high-dose arm vs 91% for low-
dose arm). Recognising the high rate of false-positive PET reports, endobronchial 
ultrasound (EBUS) is now used in routine clinical practice for the staging of stage 3 NSCLC. 
Given the high risk of brain metastases in stage 3 NSCLC, brain imaging is the standard of 
care for patients considered for cCRT in many centres. Heterogeneity exists between 
centres in the modality of brain imaging used with CT, MR, and thin-slice MR available. 
Neither EBUS nor brain imaging usage was standardised in studies such as RTOG 0617 
causing a potential imbalance of stage of disease in different dose arms. 
. 
Genetic and histopathological heterogeneity 
Due to the carcinogenic effect of cigarette smoke, lung cancers have one the highest 
mutational burdens of any cancer [34]. Therefore mutational drivers of lung cancer are 
heterogeneous and known therapeutically targetable drivers such as EGFR, EML4-ALK and 
ROS1 affect only a small proportion of cases, particularly in smokers. In one study patients 
with tumours harbouring activating mutations in EGFR who receive cCRT have longer local 
control and fewer local relapses than those without activating EGFR mutations [35]. 
Conversely another study found that patients with hotspot KRAS mutations had shorter 
median relapse-free survival and poorer response rates following cCRT [36]. Another 
interesting but unexplained observation is that maintenance gefitinib (EGFR tyrosine kinase 
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inhibitor) in molecularly unselected post cCRT patients gave worse survival [15]. Therefore 
there is much to learn about the molecular determinants and mechanisms of radiosensitivity 
and normal tissue toxicity. While randomisation may dilute varying radiosensitivity and 
tumour molecular characteristics, more precise molecular classification to stratify patients 
needs to be a major focus of future trials. In RTOG 0617 the addition of the EGFR inhibitor 
(cetuximab) to cCRT did not confer any survival benefit [9]. No prospective genetic 
stratification occurred although a planned retrospective analysis suggested that patients with 
high EGFR expressing tumours might receive a survival benefit with cetuximab (42.0 vs. 
21.2 months median OS, p=0.032) as opposed to patients with low EGFR expressing 
tumours that might do worse with cetuximab (19.5 vs. 29.6 months median OS, p=0.056). In 
RTOG 0617 patients were stratified for histological subtype and no subtype was associated 
with a better survival on multivariate analysis. However, stage 4 chemotherapy NSCLC trials 
have demonstrated that there is a difference in response to chemotherapy regimens based 
on histological subtype [12]. Data from cone-beam CT imaging that verifies the accuracy of 
radiotherapy delivery during treatment suggests a correlation between rapid shrinkage and 
poorer outcome for non-adenocarcinoma but not rapidly shrinking adenocarcinoma histology 
in patients receiving cCRT [37]. Furthermore, histopathological evaluation of surgical 
specimens indicates that a larger clinical target volume (CTV) may be required for 
adenocarcinoma compared to squamous to ensure adequate coverage of microscopic 
disease [38].  Therefore, whilst there is currently no robust data to claim that different 
histological subtypes have different outcomes to cCRT, future trials should be designed to 
ensure adequate power for known molecular and histological subtypes. 
 
Radiotherapy heterogeneity 
Within the same dose-fractionation, the delivery of radiotherapy varies greatly between 
centres regarding technology used, target volumes, organs at risk (OAR) tolerances, set-up 
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protocols and care throughout treatment. Within departments, where the above variables are 
expected to be constant, there is often great variability between clinicians in terms of target 
delineation [39]. Therefore radiotherapy for stage 3 NSCLC is delivered in a very 
heterogeneous manner that could confound trial results. The simplest intervention is to 
introduce radiotherapy QA into the trial protocol so that the same planning methods, OAR 
tolerances and target volumes are used between participating centres. This was done to 
some extent for RTOG 0617 (OAR constraints were recommended but not mandated) and in 
NCT00686959 (evaluating different chemotherapy regimens in cCRT) but radiotherapy QA 
has been lacking for other major studies. In RTOG 0617 patients were recruited from 185 
centres with a median of only 2 cases per centre. Despite a QA protocol for RT planning and 
delivery there was significant disparity between the two dose arms with a significantly higher 
rate of protocol non-compliance (26% vs. 17% p=0.02) in the high dose arm [9]. Also 
treatment delays were longer and contouring was poorer in the high dose arm. These 
disparities could be explained in part by inexperience with the higher dose in centres with a 
low volume of patients. The authors of RTOG 0617 highlighted the potential effects of using 
a large number of participating centres by publishing subsequent analysis of the RTOG 0617 
data along with data from the phase I/II dose-escalation study [40][41]. Separating outcomes 
into those treated at low volume centres (LVC – 3 or less patients enrolled) and high volume 
centres (HVC – more than 3 patients) revealed that patients from the HVCs had statistically 
superior OS, PFS and mean heart dose [40]. In data from the early phase dose-escalation 
study there was a very high median survival for stage 3 patients (39.8 months) suggesting 
benefit to dose-escalation [41]. The discrepancy of this result compared to the larger 
subsequent phase III trial was attributed to lower heart doses and also plans being double 
checked by experienced staff to ensure protocol compliance in the smaller phase I/II study 
[41].  
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Data from an unplanned subset analysis of the RTOG 0617 patients whose RT treatment 
plans were compliant to the planning and contouring protocol showed the detriment of dose-
escalation on survival remained. Examining the protocol reveals permitted variations in 
radiotherapy planning between centres. There is flexibility in the GTV to CTV expansion, 
allowing 0.5-1.0cm. Secondly, to allow for challenging critical structure geometry, the 
prescribed dose was allowed to cover as little as 90% of the PTV. Finally the heart was 
ranked lowest (behind spinal cord, lungs, oesophagus, and brachial plexus) in terms of 
priority for meeting normal tissue dose constrains and the limits to the heart (60Gy to <1/3, 
45Gy to <2/3, and 40Gy to <100% of the heart) are relatively high and not mandatory. In 
addition it has been shown elsewhere that despite detailed contouring protocols there is still 
significant inter-clinician variability in contouring target volumes in NSCLC [42].  
 
Clinical trials across multiple institutions over long time periods must account for changes in 
the technology used to plan or deliver the radiotherapy. The last decade has seen a shift 
from a 3D conformal approach (3DCRT) to the use of Intensity Modulated Radiotherapy 
(IMRT). Stratification occurred in RTOG 0617 to give equal numbers of 3DCRT and IMRT in 
the treatment arms. A subsequent analysis showed no difference in OS or local control 
between the two techniques although patients treated with IMRT had larger PTVs, more 
stage 3B disease, and worse socioeconomic demographics [43]. It was proposed that as 
IMRT and 3DCRT had similar outcomes the use of IMRT might have mitigated against these 
potential negative impacts on survival. It was also found that IMRT patients had lower heart 
and lung doses, fewer grade 3 pneumonitis episodes, and better quality of life post treatment 
[43][44]. No prospective randomised datasets demonstrate a survival benefit of IMRT over 
3DCRT although some retrospective series support the finding that IMRT offers equivalent 
survival for poorer prognosis tumours and reduces normal tissue irradiation. A recent 
retrospective analysis of 7492 stage 3 NSCLC patients treated between 2003 – 2011, of 
which 10% received IMRT, showed a small but significant advantage in OS versus non-
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IMRT treatments [45]. The availability of IMRT may influence the clinical decision of whether 
or not a curative dose of cCRT can be safely delivered. The stratification of IMRT and 
3DCRT in RTOG 0617 prevented bias in this regard. An emerging technology is four-
dimensional CT (4DCT) radiotherapy planning that takes account of the motion of the 
tumour in the respiratory cycle to prevent geographical misses. Like the advanced 
technologies that preceded it, there is currently variation in the use of 4DCT between 
centres. There is also heterogeneity between 4DCT centres regarding methods used for 
reconstruction of the imaging data and the protocols used for image acquisition. 
 
Clinical response heterogeneity 
There is conflicting data on the prognostic value of tumour shrinkage during and immediately 
post-cCRT for stage 3 NSCLC. In one retrospective study the GTVs pre-treatment and 1-
month post-treatment, as assessed by CT, were analysed for 157 patients [21]. This 
showed, in concordance with previous studies, that patients with smaller pre-treatment 
GTVs had better survival. However they also found a trend to worse OS with a larger volume 
reduction ratio (indicating better short-term response to treatment) in a multivariate model 
(p=0.075) [21]. Another study of 99 patients undergoing RT and cCRT supported this finding 
using an automated analysis of tumour regression on cone-beam CT scans during treatment 
to show that pronounced tumour regression was associated with worse loco-regional control 
and OS [37]. Conflicting data from another study shows better survival in patients with 
greater tumour regression on cone-beam imaging during cCRT [46]. Differences between all 
3 studies may account for the conflicting results such as assessment time points, patient 
demographics, and method of tumour measurement. However it is clear that the era of cone-
beam treatment imaging has revealed heterogeneity between tumours regarding early 
response to cCRT and further work may identify those patients more likely to benefit from 
treatment intensification such as dose-escalation. Weight loss throughout treatment may 
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also indicate those patients with a poor prognosis. This was initially described in stage 3 
patients receiving cCRT who lost weight between the first and last day of treatment with 
inferior OS and PFS in patients whose body mass index reduced by 0.5kg/m2 over this time 
[47].  Early weight loss (5% loss between the start and third week of radiotherapy) is also 
associated with a significantly poorer OS [48]. In this study all patients were weight-stable 
prior to the commencement of cCRT and received weekly dietetic support. The weight loss 
group had similar toxicities, chemotherapy doses, and GTVs so the mechanism for poorer 
outcome is not known. However it appears the detriment associated with early weight loss is 
not merely a surrogate for locally advanced disease or de-escalation of treatment. Further 
work is required before early weight change can be used as clinical biomarker but in the 
future this observation may guide decisions regarding dose-escalated treatment. 
 
Determination of local relapse post-radiotherapy for lung tumours is notoriously difficult even 
for experienced radiologists due to fibrotic changes caused by radiation. In one study of 50 
patients who received hypofractionated lung radiotherapy, 20 patients had abnormalities 
deemed suspicious for recurrence (at a median of 20.7 months) yet only 3 of those were 
proven to have recurred on further follow-up [49]. Most data on the challenges associated 
with radiotherapy response assessment come from hypofractionated studies where 
increased dose per fraction appears to enhance the fibrotic and inflammatory response [50]. 
The effect of dose-escalation on severity of fibrosis is not quantified and it is possible that 
the high incidence of local recurrence reported in some studies could be a consequence, at 
least in part, of misinterpretation. This effect could be compounded by the aforementioned 
heterogeneity in participating institutions of RTOG 0617 in which radiologists may have 
misinterpreted CT scans as showing local recurrence. Data suggests that differing 
radiotherapy techniques can influence the appearance of fibrosis, adding further potential 
heterogeneity between centres [51]. The use of PET scanning may be beneficial to 
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distinguish fibrosis from recurrence [52], but again heterogeneity in its use between centres 
is problematic for the interpretation of trial results. 
 
Currently available solutions and future directions  
Despite the disappointing results of RTOG 0617, a number of studies are currently 
evaluating treatment intensification in stage 3 NSCLC. As things stand currently there are 2 
key questions. Firstly is there enough evidence of a potential benefit to dose-escalation in 
stage 3 NSCLC cCRT to justify further trials? Secondly how could these new trials be 
optimised to ensure a benefit (or conclusive negative result) is detected? Regarding 
evidence of potential benefit from dose-escalation, the justification for RTOG 0617 was 
based upon radiobiological calculations that dose-escalation should improve outcome in 
stage 3 NSCLC [4]. Following RTOG 0617, the publication of initial early phase data 
showing a benefit of dose-escalation and the identified shortcomings of the original phase III 
trial justify further exploration of dose-escalation, but employing individualised regimens 
rather than a single fixed dose based on 2Gy per fraction [41]. The question of how to 
optimise further trials is more complex as the sections above have illustrated the factors that 
make stage 3 NSCLC such a heterogeneous group.  Unless these factors are controlled for 
in phase III trials then there is a risk they could compromise trial results as suggested by 
subsequent analyses of RTOG 0617. Table 1 summarises potential solutions available to 
limit the effects of heterogeneity in NSCLC. Some of these solutions are based upon current 
evidence and could be implemented immediately whereas some are based upon promising 
technologies in development that are yet to be proven beneficial. Strategies such as isotoxic 
radiotherapy, functional boosting, and adaptive techniques all aim to improve survival 
through superior local control via dose escalation whilst limiting normal tissue dose. Others 
are solutions that may be employed to better balance trial arms for risk of metastatic disease 
and prognosis and enhance the ability to demonstrate benefit. 
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 Regarding measures that could be made immediately an important starting point is to 
determine what stages of disease should be included in future trials and whether 
stratification by AJCC staging should be replaced by other variables such as total GTV. 
Similar considerations may be made regarding the anatomical location of tumours such as 
tumour centrality. Other immediately available measures are enhancing QA and protocols, 
regulated use of different technologies, and centralising aspects of the trial such as 
diagnosis of relapse or plan review. 
 
Current technology allows approaches that permit the heterogeneity of NSCLC to be 
embraced in treatment planning to produce individualised escalated doses with the aim of 
improving local control. Isotoxic radiotherapy aims to increase the tumour dose by allowing 
an individualised dose prescription of radiotherapy that can be escalated up to a maximum 
as long as OAR dose tolerances are not exceeded. An in silico exercise found that a twice-
daily accelerated radiotherapy regimen with total dose determined by an individualised 
maximal tolerated dose led to superior tumour control probability to standard dose 
fractionations [53]. An early phase feasibility study showed accelerated individualised dose 
prescriptions allowed escalated doses to be safely delivered to the tumour (no excess 
toxicity and comparable survival) [54][55]. The original study used 3DCRT so 2 further 
studies have been conducted in the UK (ClinicalTrials.gov:NCT01836692) and the 
Netherlands (ClinicalTrials.gov:NCT01166204) using IMRT alongside 4DCT planning and 
image guided radiotherapy techniques with the hypothesis that these technologies will allow 
safe dose-escalation to the tumour without breaching OAR tolerances [56].  
 
Combining functional imaging data may identify regions of tumours that will benefit from a 
dose-escalation boost to improve local control.  Using imaging pre and post-radiotherapy it 
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was shown that residual PET avid areas post-treatment correspond to poorer prognosis and 
these areas correspond to regions on the pre-treatment scan with the highest avidity 
[57][58]. A phase II randomised trial investigated the feasibility of delivering dose-escalation 
to PET avid regions and demonstrated it is possible to boost dose to PET avid lesions to 
86.9 +/- 14.9Gy without excess OAR dose [59]. Another phase II trial has demonstrated 
favourable local control and survival using a mid-treatment PET-CT scan to give escalated 
doses to residual tumour [60].  This approach is now being evaluated in a phase 3 trial using 
PET scanning midway though the radiotherapy course and either continuation to 
conventional 60Gy in 30# or adaptive planning with dose-escalation to PET avid regions up 
to a total of 80.4Gy in 30# (RTOG 1106). [18F]-Fluoromisonidazole (F-MISO) is a tracer 
used in functional imaging to identify areas of hypoxia [61]. A phase II study has been 
performed using F-MISO imaging to identify areas to deliver dose-escalated boost resulting 
in doses of up to 86Gy [62]. In this study there was no reported extra toxicity with dose-
escalation and, whilst it concluded that dose-escalation could not reverse the poor prognosis 
of F-MISO positive patients, further work is required to see if dose-escalation to hypoxic 
regions is beneficial. Using other advances trials are assessing the benefits of dose-
escalation to peripheral primaries using hypofractionated SBRT whilst delivering 
conventional fractionated radiotherapy to mediastinal lymph nodes 
(ClinicalTrials.gov:NCT01933568).  
 
Adaptive radiotherapy may improve the accuracy of radiotherapy delivery, ensuring that 
geographical misses and OAR doses do not dilute the benefits of dose-escalation. In the 
LARTIA trial patients undergoing cCRT for stage 3 NSCLC received weekly CT scans and 
were re-planned if there was tumour shrinkage [63]. Re-planning was performed in 50 of 217 
patients with 42% average reduction of CTV between initial planning and re-planning CTs. 
Compared to historical data the re-planned patients had lower pulmonary toxicity. The infield 
(within re-planned CTV) and marginal (within initial but not re-planned CTV) relapses were 
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20% and 6% respectively suggesting that routine re-planning of shrunken CTVs is safe to 
reduce toxicity and allow the dose-escalation to tumours in proximity to critical regions that 
shrink significantly during treatment. It is hoped the use of linear accelerators with integrated 
MR imaging will allow enhanced adaptive radiotherapy and the superior conformality of 
protons may allow dose-escalation to central regions whilst keeping OAR doses within 
tolerance [64].   
 
Looking to future technological advancements it may be possible to use radiomics 
characteristics to stratify patients. Radiomics describes the use of imaging modalities to 
extract quantitative data (such as size, shape and texture of a tumour) that can be used to 
characterise the phenotypes of different tumours and predict clinical outcomes [65]. In 
addition radiomics can be performed non-invasively at multiple time-points allowing temporal 
assessment of a tumour [66].  Whilst this is a relatively new field, work has already 
demonstrated how radiomics signatures can be prognostic in NSCLC patients receiving 
radiotherapy [67]. Therefore determining inclusion criteria using radiomics features 
associated with lower risk of occult metastases may be an effective strategy to identify a trial 
population with a greater potential benefit from dose-escalation. Further ahead it is 
envisioned that artificial intelligence will be applied to radiomics data to aid and automate 
tumour and OAR delineation [68]. 
 
Large sequencing studies have demonstrated that, despite their high mutational burden, 
actionable genetic drivers are unknown for a majority of NSCLC [69]. Functional biological 
studies are required to identify more drivers so that targeted agents can be trialled 
concurrently with cCRT. Genomic signatures have been validated in other tumour subtypes 
to identify specific tumours with poorer responses to radiotherapy [70][71]. Hopefully similar 
signatures could be developed for NSCLC so that patients with radioresistant tumours could 
AC
CE
PT
ED
 M
AN
US
CR
IPT
be identified as potential beneficiaries of dose-escalation. In a similar vein, genomic profiles 
may be used to detect patients more likely to benefit from the addition of immune checkpoint 
inhibitors to their treatment. The difficulties of determining relapse may also be aided by new 
biological technologies, for example circulating tumour DNA (ctDNA) profiling has been 
demonstrated to detect disease relapse earlier than conventional radiology in patients 
undergoing resection of stage 1-3 NSCLC in the TRACER-X study [72]. It is conceivable that 
the incorporation of circulating biomarkers could aid in the delivery and intensification of RT 
in patients with stage 3 unresectable NSCLC. Biological methods of relapse detection may 
also augment radiological methods to improve and standardise assessment of response as 
well as identify patients with a high risk of relapse who should be spared the toxicity of 
cCRT.  
 
Conclusion 
We have highlighted multiple levels of heterogeneity between cases of stage 3 NSCLC and 
for future studies a priority is to ensure better equality in trial arms for newly identified 
prognostic factors. It may be argued that using large numbers of patients in randomised 
arms protects against some of these factors. However these potentially confounding factors 
need to be considered at the trial planning stage so that the benefits of stratification can be 
realised and factors that may result from differences in the treatment schedules (such as 
heart dose or anatomical location) can be controlled using dose constraints or protocol 
definitions. There is a balance to be achieved, as if trial entry criteria are too prescriptive it 
reduces the pool of eligible trial participants and limits the application of results to large 
segments of the actual patient population. However lung cancer is one of the most common 
cancers therefore it is conceivable that trials could be more selective with regards to entry 
criteria for subtypes of stage 3 and still enrol adequate numbers. This may provide evidence 
needed to justify dose-escalation trials in higher-risk patients using emerging technologies to 
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limit dose to critical structures. Another priority is the use of new technology, QA, and 
diagnostics to be standardised across multicentre trials. Critical facets of this approach such 
as central review of diagnostics are expensive and radiotherapy trials, disadvantaged by 
lack of pharmaceutical industry funding, need a collaborative approach to solve this. In 
summary, despite radiobiological rational and logical assumption there is currently paucity of 
modern phase III data for any cancer subtype showing survival benefit for dose-escalation 
with external beam radiotherapy in stage 3 disease. However despite the negative finding in 
RTOG 0617, there is enough justification to support further investigation into dose-escalated 
cCRT. Recent technological advances and the knowledge acquired from subsequent 
analyses of RTOG 0617 offer novel opportunities to safely assess dose-escalation in 
NSCLC and hopefully redress previous limiting factors to improve patient outcomes.   
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Table 1 – Sources of heterogeneity and solutions to balance trial arms 
Source of heterogeneity 
 
Solutions 
Currently available Potential future strategies 
Tumour characteristics / 
Staging 
 Diverse clinical 
presentations account 
for same stage 
 Gross tumour volume 
(primary and nodes) 
 Number / location of 
involved nodes 
 Stratify / exclude cases 
into smaller prognostic 
groups based on: 
- GTV 
- Number of lymph 
nodes 
 
 Stratify / exclude cases into 
smaller prognostic groups 
based on: 
- Radiomic features 
Anatomical 
 Proximity to critical 
structures e.g. heart 
 Tumour motion 
variability 
 Isotoxic radiotherapy to 
individualise treatment 
based on proximity of 
OAR 
 Stratify / exclude cases 
into smaller prognostic 
groups based on 
anatomical location. 
 Better dose sparing of OAR 
(e.g. heart) using 
 
- Improved ‘beam-on’ 
imaging of tumour and 
OAR with MR-guided 
radiotherapy 
 
- Proton beam 
radiotherapy 
Genetic / Histopathological 
 Diverse genetic drivers 
– many unknown / 
some sensitising 
 EGFR expression 
 Squamous vs. non-
squamous histology 
 Stratify / exclude genetic 
or histopathological 
subtypes e.g. EGFR 
mutant / squamous 
histology 
 Identify biomarkers of 
intrinsic radiosensitivity for 
stratification 
Radiotherapy 
 Radiotherapy quality 
assurance 
 Centre Experience (high 
volume vs. low volume 
 Stratify use of advanced 
technology (e.g. 4DCT 
planning) 
 
 Comprehensive 
radiotherapy QA / 
centralised radiotherapy 
 Automation of radiotherapy 
planning tasks e.g. target 
and OAR delineation. 
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centres) 
 Technology – IMRT / 
PETCT/ 4D planning / 
IGRT and adaptive 
radiotherapy 
plan review / site 
training 
Clinical Response 
 Tumour shrinkage 
during treatment 
 Weight loss 
 Image-guidance and 
adaptive radiotherapy 
 
 Nutrition / dietician 
support 
 Functional imaging 
acquired during 
radiotherapy to adapt 
treatment. 
 
Diagnostic 
 Use of PET / EBUS / 
brain imaging to stage 
patient 
 Definition of local 
relapse 
 Centralise relapse 
definition 
 Enhanced imaging for 
relapse e.g. PET 
 
 Biological markers of 
relapse e.g. cfDNA 
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Table 1 – Sources of heterogeneity and solutions to balance trial arms 
Source of heterogeneity 
 
Solutions 
Currently available Potential future strategies 
Tumour characteristics / 
Staging 
 Diverse clinical 
presentations account 
for same stage 
 Gross tumour volume 
(primary and nodes) 
 Number / location of 
involved nodes 
 Stratify / exclude cases 
into smaller prognostic 
groups based on: 
- GTV 
- Number of lymph 
nodes 
 
 Stratify / exclude cases into 
smaller prognostic groups 
based on: 
- Radiomic features 
Anatomical 
 Proximity to critical 
structures e.g. heart 
 Tumour motion 
variability 
 Isotoxic radiotherapy to 
individualise treatment 
based on proximity of 
OAR 
 Stratify / exclude cases 
into smaller prognostic 
groups based on 
anatomical location. 
 Better dose sparing of OAR 
(e.g. heart) using 
 
- Improved ‘beam-on’ 
imaging of tumour and 
OAR with MR-guided 
radiotherapy 
 
- Proton beam 
radiotherapy 
Genetic / Histopathological 
 Diverse genetic drivers 
– many unknown / 
some sensitising 
 EGFR expression 
 Squamous vs. non-
squamous histology 
 Stratify / exclude genetic 
or histopathological 
subtypes e.g. EGFR 
mutant / squamous 
histology 
 Identify biomarkers of 
intrinsic radiosensitivity for 
stratification 
Radiotherapy 
 Radiotherapy quality 
assurance 
 Centre Experience (high 
volume vs. low volume 
 Stratify use of advanced 
technology (e.g. 4DCT 
planning) 
 
 Comprehensive 
radiotherapy QA / 
centralised radiotherapy 
 Automation of radiotherapy 
planning tasks e.g. target 
and OAR delineation. 
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centres) 
 Technology – IMRT / 
PETCT/ 4D planning / 
IGRT and adaptive 
radiotherapy 
plan review / site 
training 
Clinical Response 
 Tumour shrinkage 
during treatment 
 Weight loss 
 Image-guidance and 
adaptive radiotherapy 
 
 Nutrition / dietician 
support 
 Functional imaging 
acquired during 
radiotherapy to adapt 
treatment. 
 
Diagnostic 
 Use of PET / EBUS / 
brain imaging to stage 
patient 
 Definition of local 
relapse 
 Centralise relapse 
definition 
 Enhanced imaging for 
relapse e.g. PET 
 
 Biological markers of 
relapse e.g. cfDNA 
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